3 completed, 1 withdrawn. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow ecallantide: new trials by email Literature Review of ecallantide trials Research Report on ecallantide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema ecallantide - Hereditary Angioedema (HAE) | Phase 2 / Phase 3 | Withdrawn | Shire | 2012-06-01 | 2021-05-18 | |
| Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) ecallantide, Phosphate Buffer Saline (PBS), pH 7.0 - Hereditary Angioedema (HAE) | Phase 3 | Completed | Shire | 96 | 2007-04-01 | 2021-06-08 |
| Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) ecallantide - Hereditary Angioedema (HAE) | Phase 3 | Completed | Shire | 147 | 2007-04-01 | 2021-06-08 |
| Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) ecallantide, Phosphate Buffer Saline (PBS), - Hereditary Angioedema (HAE) | Phase 3 | Completed | Shire | 91 | 2005-12-31 | 2021-06-11 |
Shire (4)
United States (3) · Canada (2) · Jordan (2)
PMID 23548529, PMID 23878046, PMID 24712435, PMID 21130380, PMID 22765833, PMID 23548526, PMID 20818887